Literature DB >> 23487233

Sodium benzoate, a D-amino acid oxidase inhibitor, increased volumes of thalamus, amygdala, and brainstem in a drug-naïve patient with major depression.

Chien-Han Lai.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23487233     DOI： 10.1176/appi.neuropsych.12030056

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN： 0895-0172            Impact factor:   2.198


× No keyword cloud information.
  3 in total

1.  Gut-brain axis metabolic pathway regulates antidepressant efficacy of albiflorin.

Authors:  Zhen-Xiong Zhao; Jie Fu; Shu-Rong Ma; Ran Peng; Jin-Bo Yu; Lin Cong; Li-Bin Pan; Zuo-Guang Zhang; Hui Tian; Chun-Tao Che; Yan Wang; Jian-Dong Jiang
Journal:  Theranostics       Date:  2018-11-13       Impact factor: 11.556

Review 2.  Sodium Benzoate-Harmfulness and Potential Use in Therapies for Disorders Related to the Nervous System: A Review.

Authors:  Łucja Justyna Walczak-Nowicka; Mariola Herbet
Journal:  Nutrients       Date:  2022-04-02       Impact factor: 5.717

3.  The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - CADENCE-BZ: study protocol for a randomized controlled trial.

Authors:  Alex Ryan; Andrea Baker; Frances Dark; Sharon Foley; Anne Gordon; Sean Hatherill; Stephen Stathis; Sukanta Saha; George Bruxner; Martin Beckman; Drew Richardson; Michael Berk; Olivia Dean; John McGrath; Cadence Working Group; James Scott
Journal:  Trials       Date:  2017-04-07       Impact factor: 2.279
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.